Jamjoom Pharma’s 2024 Profit Rises 22% to SAR 356 Million

Jamjoom Pharmaceuticals Factory Co. (the “Company”) announced on Tuesday that its net profit rose by 22% to SAR 356 million by the end of 2024, compared to SAR 292 million last year, following the announcement today of the preliminary financial results for the duration ending Dec. 31, 2024.

The operational profit increased by 22% to SAR 381 million by the end of 2024, compared to SAR 313 million last year.

The equity (after excluding non-controlling interests) in the current year increased by 6% to SAR 1.49 billion, compared to SAR 1.4 billion last year.

The profits per share in the current year amounted to SAR 5.1, compared to SAR 4.2 last year.

The Company stated in a statement today on “Tadawul” that the current year’s revenues increased by 19.8% compared to the previous year, driven by successful strategic initiatives to expand sales in key markets and therapeutic areas. This growth was supported by the launch of new products and the improvement of manufacturing capabilities, thanks to the modern facilities that were commissioned in Egypt and the Kingdom of Saudi Arabia. In addition, the general expansion in the pharmaceutical market contributed to achieving a strong performance at the revenue level.